特发性身材矮小儿童成骨细胞的功能状况

目的通过检测特发性身材矮小(ISS)儿童血清骨碱性磷酸酶(BAP)及骨钙蛋白(OC)水平,探讨其成骨细胞的功能状况。方法ISS组36例及健康对照组儿童50例。ISS组分为青春期前组及青春期组。测各组儿童身高、体质量、体质量指数,采用CHN法评定左侧手、腕部骨化指标,计算骨龄。采用ELISA法测其血清BAP及OC水平。结果青春期前,ISS儿童血清BAP及OC水平为(79.90±25.96)U/Lvs(60.96±18.46)μg/L,健康对照组为(152.17±35.36)U/Lvs(76.16±28.03)μg/L;青春期,ISS儿童血清BAP及OC水平为(108.33±35.20)U/Lvs(63.82±24.81)μg/L,健康对照组为(156.30±35.29)U/Lvs(104.92±28.26)μg/L。青春期前及青春期ISS组血清BAP及OC水平均明显低于健康对照组,存在显著性差异(Pa<0.01)。结论ISS儿童以成骨细胞为中心环节的骨塑造和再造能力均较健康生长发育少年儿童差。     

膦甲酸钠干预高磷诱导的血管平滑肌细胞钙化的研究

目的　观察不同浓度的膦甲酸钠 (PFA)对高磷诱导的牛主动脉血管平滑肌细胞钙沉积和骨钙素 (OC)表达的影响。方法　用不同磷浓度 (正常磷Pi1.5mmol·L-1、高磷Pi2 0mmol·L-1)及含不同浓度膦甲酸钠的培养液 ,体外培养牛主动脉平滑肌细胞 ,观察血管平滑肌细胞钙沉积及骨钙素表达。用甲ο 酚酞络合酮方法测定钙含量 ,BCA法测定蛋白含量。培养上清液中骨钙素浓度用放射免疫法测定 ,用蛋白含量标化钙含量、骨钙素的浓度 ,RT PCR观察骨钙素mR NA的表达。结果　①高磷组较正常磷组平滑肌细胞钙沉积增加 :细胞培养 6d后 ,高磷组 (77 187± 11 6 92 )mg·g-1Pro ,正常磷组 (2 5 76 8± 1 75 0 )mg·g-1Pro ,P <0 0 1;②膦甲酸钠能有效地抑制钙沉积 :培养 6d ,高磷 +PFA 1 0mmol·L-1组 (37 72 9± 5 899)mg·g-1Pro ,与高磷未干预组相比 ,P <0 0 1;③高磷组骨钙素表达明显增高。高磷组与正常磷组相比 ,培养上清液中骨钙素水平 :(1 5 0 3× 10 -2 ±2 6 0 1× 10 -3 )mg·g-1Pro对 (2 981× 10 -3 ± 8 382× 10 -4)mg·g-1Pro ,P <0 0 1;平滑肌细胞骨钙素mRNA表达 (OC/GAPDH) :1 886± 0 16 5对 0 75 2± 0 0 5 2 1,P <0 0 1;④膦甲酸钠能有效地抑制骨钙素的表达。高磷 +PFA 1 0mmol·L-1组与高磷组?     

Development and Application of a Serum C-Telopeptide and Osteocalcin Assay to Measure Bone Turnover in an Ovariectomized Rat Model

Biochemical markers applicable to the ovariectomized rat model can provide important tools for studying the bone remodeling process in this animal model of postmenopausal osteoporosis. We describe the development and application of two biochemical markers, a C-telopeptide (of type-I collagen) enzyme-linked immunosorbent assay (ELISA) for measuring bone resorption and an osteocalcin radioimmunoassay (RIA) for measuring bone formation in rat serum. The C-telopeptide ELISA is based on an affinity purified polyclonal antibody generated against human sequence DFSFLPQPPQEKAHDGGR. The antibody epitope involves amino acid sequence, which is similar in rat and human carboxyl terminal peptide of type-I (alpha 1) collagen. Sensitivity of the ELISA was 0.3 ng/ml. The averaged intra- and interassay variation was CV <7%. Averaged dilution and spiked recoveries were 91% and 105%, respectively. The second marker developed is a synthetic peptide-based osteocalcin RIA, which does not require isolation and purification of intact osteocalcin from rat bone. Osteocalcin antiserum used in the RIA was generated in rabbits against a synthetic peptide comprising amino acids 33–49 of the rat osteocalcin sequence. The sensitivity of the RIA was 0.15 ng/ml of peptide. The averaged intra (n = 10) and interassay variations for two controls were CV <9% and 12%, respectively. The averaged dilution and spiked recoveries were 99.6%. In vivo validation of the C-telopeptide ELISA and osteocalcin RIA was performed in an ovariectomized (OVX) rat model. In 12-week-old OVX Sprague Dawley rats, the C-telopeptide and osteocalcin concentrations were approximately 65% and 40%, respectively, higher than the sham group. Estradiol repletion significantly lowered the C-telopeptide and osteocalcin concentration to the levels of the sham group. In addition, changes in serum C-telopeptide concentration correlated negatively with trabecular BMD measured by pQCT (r =−0.51, P < 0.001). In conclusion, the C-telopeptide ELISA and osteocalcin RIA exhibited required sensitivity, accuracy, and adequate discriminatory power to be used for measuring bone resorption and bone formation in the ovariectomized rat model. Received: 20 August 1999 / Accepted: 5 January 2000     

联合补充不同剂量钙、镁、铜、锌和维生素D对中老年妇女骨质疏松症的防治效果

目的观察联合补充钙、镁、锌、铜及维生素D对中老年妇女骨密度和骨钙索的影响，以及改善骨症状的效果。方法依据人选和排除标准，在上海地区筛选出中老年妇女230人，随机分成干预组和对照组，各组再分为未绝经与绝经组。干预组A：未绝经妇女75名；对照组A：未绝经妇女40名；干预组B：已绝经妇女78名；对照组B：已绝经妇女37名。干预组每日服用2片钙尔奇添佳片（每片含钙273．5mg、VitD1．62μg、镁99．7mg、锌3．08mg、铜0．51mg），干预6个月后再进一步分成低剂量亚组和高剂量亚组，每日服用2或3片钙尔奇添佳片，再干预6个月，总计干预12个月。所有入选者在研究前后各阶段检测腰椎骨密度（BMD）及血清骨钙素（BGP），并进行24小时膳食回顾调查和记录骨症状改善情况。结果（1）骨密度：研究6个月后，干预组腰椎骨密度值较前无显著差异（P〉0．05）。研究12个月后，未绝经干预组骨密度显著增加，未绝经对照组腰椎骨密度则呈显著性下降，但已绝经干预组和对照组的骨密度研究前后无显著变化（P〉0．05）。不同剂量干预亚组骨密度间无显著差异（P〉0．05）。（2）骨钙素：研究6及12个月后各组骨钙素水平均明显降低（P〈0．05）；但干预组血清骨钙素水平均明显高于对照组，差异有显著性（P〈0．05）。不同剂量干预亚组的血清骨钙素浓度间无显著差异（P〉0．05）。（3）骨症状：干预后能明显改善局部关节痛和腰背痛等骨症状。结论联合补充钙、镁、锌、铜及维生素D可明显增加未绝经妇女的骨密度和骨钙索，有效改善骨症状；并可明显改善已绝经妇女骨钙素及骨症状，但骨密度改善不明显。低剂量亚组与高剂量亚组的骨质疏松防治效果问无显著性差异。建议中老年妇女尽早补充与骨营养有关的营养素以防治骨质丢失。     

辛伐他汀对骨质疏松大鼠血清骨钙素及骨密度的影响

目的:研究辛伐他汀对骨质疏松大鼠骨密度及血清骨钙素的影响,探讨其促进骨形成的作用。方法:36只雌性Wistar大鼠,随机分为4组。A组为假手术组,其余各组均行双侧卵巢切除术,术后1wk开始,A,B两组每只大鼠灌服生理盐水1.5mL·d-1,C组予辛伐他汀5mg·kg-1·d-1,D组予尼尔雌醇0.01mg·kg-1·d-1。10wk后处死大鼠,测量大鼠体重、股骨骨密度和血清骨钙素。结果:10wk后,B组大鼠体重高于A组,C,D组大鼠体重低于B组,均P<0.01。C,D组股骨骨密度(0.245±s0.007),(0.2430±0.0010)g·cm-2,高于B组(0.245±0.009)g·cm-2,血清骨钙素水平亦高于B组,均P<0.05,2组之间差异无显著意义(P>0.05)。结论:辛伐他汀能增加骨质疏松大鼠骨密度,提高骨钙素水平,促进新骨形成。     

不同糖耐量者血清骨钙素水平的比较性研究

目的比较不同糖耐量者其骨钙素(OC)水平并探讨骨钙素与各代谢相关指标的相关性。方法根据WHO1999年诊断标准,收集门诊及住院患者,其中正常糖耐量组(NGT)13人、空腹血糖调节受损组(IFG)10人、新诊断的2型糖尿病(T2DM)29人,ELISA法测定骨钙素水平并采集相关的生化参数,不同组别间的OC比较采用单因素方差分析,BMI、TC、TG、HDL-C、LDL-C、HbA1c及HOMA-IR与OC的相关性采用Person相关分析。结果 2型糖尿病患者其OC水平较NGT及IFG患者其OC水平明显降低,其浓度从NGT到IFG再到T2DM逐渐降低。相关分析表明OC与FBG、HbA1C、HOMA-IR、TC、LDL-C成负相关,有统计学意义(P<0.05);OC与BMI、INS、TG、HDL-C无相关关系,无统计学意义(P>0.05)。结论骨钙素不仅与糖代谢有关而且与脂代谢有关。     

健康人群血清骨钙素影响因素的研究 —— 以北京市海淀区为例

目的了解健康人群血清OC的变化及与能量代谢的关系。方法根据排除标准筛选115名受试者(男60人,女55人),用电化学发光法和终点法检测血清OC,能量代谢指标水平,并分析血清OC与TC、TG、HDL-C、LDL-C、FINS、FPG、HOMA-IR之间的关系。结果绝经后女性OC水平与男性、绝经前女性差异存在统计学意义(P0.05)。相关性分析中,男、女性年龄与血清OC之间均呈显著负相关(r_男=-0.517和r_女=-0.568)。男、女性BMI与血清OC之间均呈显著负相关(r_男=-0.286和r_女=-0.453)。男性HDL-C与血清OC之间呈显著正相关(rHDL-C=0.271)。女性TG与血清OC之间呈显著负相关(r_(TG)=-0.340);女性HDL-C与血清OC之间呈显著正相关(rHDL-C=0.275)。男性FINS、HOMA-IR与血清OC之间呈显著负相关(r_(FINS)=-0.295,rHOMA-IR=-0.28)。女性FPG、FINS、HOMA-IR与血清OC之间无显著相关性。结论在选取的受试者中,绝经后女性血清OC水平明显低于绝经前女性,绝经后女性出现肥胖较明显。年龄、BMI与血清OC呈显著负相关,即血清OC可能导致肥胖。血清OC与机体能量代谢相关。     

观察自拟中药汤剂联合西药治疗骨质疏松的临床疗效及其对骨代谢生化指标和血中骨钙素的影响

目的观察自拟中药汤剂联合西药治疗骨质疏松的临床疗效及其对骨代谢生化指标和血中骨钙素的影响。方法 124例骨质疏松患者随机分为两组。对照组用西药治疗,治疗组在对照组基础上结合自拟中药汤剂治疗。1个月后对两组疗效及相关指标进行观察。结果治疗组治疗后总有效率显著高于对照组(P0.05);治疗组治疗后U-Ca、ALP与对照组比较具有显著性差异(P0.05);治疗组治疗后血中骨钙素明显高于对照组(P0.05);两组患者在治疗过程中均未出现明显不良反应。结论自拟中药汤剂联合西药治疗骨质疏松患者效果显著。     

Correlation between osteocalcin‐positive endothelial progenitor cells and spotty calcification in patients with coronary artery disease

Immature endothelial progenitor cells (EPC) carrying osteocalcin (OCN) might mediate vascUlar calcification in coronary artery disease (CAD). Spotty calcification within atherosclerotic plaque is associated with cardiovascular events. The aim of the present study was to assess the correlation between immature EPC levels and spotty calcification in CAD patients. In the 224 CAD patients studied, 76 had acute myocardial infarction (AMI), 102 had unstable angina pectoris (UAP), and 46 had stable angina pectoris (SAP). The levels of OCN‐positive (OCN+) EPC were analysed by flow cytometry. The status of spotty calcification was determined by cardiac computed tomography angiography. OCN+ EPC and calcium deposits were significantly increased in acute coronary artery syndrome (ACS) when compared with those in SAP patients. Positive correlation was also revealed between the number of OCN+ EPC and the frequency of spotty calcification and levels of serum high‐sensitivity C‐reactive protein (hs‐CRP) and serum alkaline phosphatase in AMI and UAP patients. In summary, the number of OCN+ EPC is positively related to the frequency of spotty calcification in ACS patients. Serum hs‐CRP and serum alkaline levels are thought to contribute to the elevation of OCN+ EPC.